Clinical implications of Brief Psychiatric Rating Scale scores

2005/09/30 by Stefan Leucht, John M. Kane, Werner Kissling +4 · 30 citations
Medicine · Arts and Humanities · #Schizophrenia research and treatment #Mental Health and Psychiatry #Bipolar Disorder and Treatment

paper · pdf · doi:10.1192/bjp.187.4.366

Abstract

BACKGROUND: Despite the widespread use of the Brief Psychiatric Rating Scale (BPRS), the clinical meaning of its total score and cut-off values used to define treatment response are unclear. AIMS: To link the BPRS to Clinical Global Impression (CGI) ratings. METHOD: Equipercentile linking of BPRS and CGI ratings from seven drug trials in acutely ill patients with schizophrenia (n=1979). RESULTS: 'Mildly ill' according to the CGI approximately corresponded to a BPRS total score of 31, 'moderately ill'to a BPRS score of 41 and'markedly ill'to a BPRS score of 53.'Minimally improved'according to the CGI score was associated with percentage BPRS reductions of 24, 27 and 30% at weeks 1, 2 and 4, respectively. The corresponding numbers for a CGI rating of 'much improved' were 44, 53 and 58%. CONCLUSIONS: The results provide a clearer understanding of how to interpret BPRS total and percentage reduction scores in clinical trials with patients acutely ill with schizophrenia who are experiencing positive symptoms.

Cited by

• Differential effects of illness and antipsychotics on cortical thinning in first episode psychosis: A randomised placebo-controlled MRI study
• Early response or nonresponse at week 2 and week 3 predict ultimate response or nonresponse in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial
• Experiences relating to intimacy, romance, and sexuality in early psychosis
• The effect of expanded access to mental health care on economic status of households with a person with a mental disorder in rural Ethiopia: a controlled before-after study
• A six-session group-based pilot intervention for alcohol and other drug use in hospitalised mentally ill young offenders
• Evidence-based guidelines for interpretation of the Panic Disorder Severity Scale. [europepmc]
• Clozapine versus typical neuroleptic medication for schizophrenia. [europepmc]
• Modulation of limbic circuitry predicts treatment response to antipsychotic medication: a functional imaging study in schizophrenia. [europepmc]
• Olanzapine versus other atypical antipsychotics for schizophrenia. [europepmc]
• Relationship of family caregiver burden with quality of care and psychopathology in a sample of Arab subjects with schizophrenia. [europepmc]
• Risperidone versus other atypical antipsychotics for schizophrenia. [europepmc]
• Psychoeducation for schizophrenia. [europepmc]
• Quantifying clinical relevance in the treatment of schizophrenia. [europepmc]
• Minimum clinically important difference in the Positive and Negative Syndrome Scale with data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). [europepmc]
• Graph theory reveals dysconnected hubs in 22q11DS and altered nodal efficiency in patients with hallucinations. [europepmc]
• The relationship between stress and social functioning in adults with autism spectrum disorder and without intellectual disability. [europepmc]
• Psychoeducation (brief) for people with serious mental illness. [europepmc]
• Crisis intervention for people with severe mental illnesses. [europepmc]
• Validation of the 17-item Hamilton Depression Rating Scale definition of response for adults with major depressive disorder using equipercentile linking to Clinical Global Impression scale ratings: analysis of Pharmacogenomic Research Network Antidepressant Medication Pharmacogenomic Study (PGRN-AMPS) data. [europepmc]
• Intensive case management for severe mental illness. [europepmc]
• Compulsory community and involuntary outpatient treatment for people with severe mental disorders. [europepmc]
• Music therapy for people with schizophrenia and schizophrenia-like disorders. [europepmc]
• How Many Patients With Schizophrenia Do Not Respond to Antipsychotic Drugs in the Short Term? An Analysis Based on Individual Patient Data From Randomized Controlled Trials. [europepmc]
• Single-Session Mobile-Augmented Intervention in Serious Mental Illness: A Three-Arm Randomized Controlled Trial. [europepmc]
• Peer support for people with schizophrenia or other serious mental illness. [europepmc]
• Interventions for prodromal stage of psychosis. [europepmc]
• Psychosocial interventions for people with both severe mental illness and substance misuse. [europepmc]
• Dying Too Soon: Excess Mortality in Severe Mental Illness. [europepmc]
• Differentiating the effect of antipsychotic medication and illness on brain volume reductions in first-episode psychosis: A Longitudinal, Randomised, Triple-blind, Placebo-controlled MRI Study. [europepmc]
• Functional Connectivity in Antipsychotic-Treated and Antipsychotic-Naive Patients With First-Episode Psychosis and Low Risk of Self-harm or Aggression: A Secondary Analysis of a Randomized Clinical Trial. [europepmc]

Related

• Using Large Language Models to Measure Symptom Severity in Patients At Risk for Schizophrenia
• The Schizophrenia Cognition Rating Scale: An Interview-Based Assessment and Its Relationship to Cognition, Real-World Functioning, and Functional Capacity
• Two Factors, Five Factors, or Both? External Validation Studies of Negative Symptom Dimensions in Schizophrenia
• Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia Program
• Implementing precision psychiatry: a systematic review of individualized prediction models for clinical practice